Free Trial

ImmunoPrecise Antibodies (IPA) Competitors

ImmunoPrecise Antibodies logo
$1.76 +0.13 (+7.98%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.73 -0.03 (-1.76%)
As of 04:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IPA vs. DSGN, VOR, ACIU, ESPR, PROK, KOD, SLS, LRMR, CRGX, and CYBN

Should you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Design Therapeutics (DSGN), Vor Biopharma (VOR), AC Immune (ACIU), Esperion Therapeutics (ESPR), ProKidney (PROK), Kodiak Sciences (KOD), SELLAS Life Sciences Group (SLS), Larimar Therapeutics (LRMR), CARGO Therapeutics (CRGX), and Cybin (CYBN). These companies are all part of the "pharmaceutical products" industry.

ImmunoPrecise Antibodies vs. Its Competitors

ImmunoPrecise Antibodies (NASDAQ:IPA) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

ImmunoPrecise Antibodies presently has a consensus price target of $4.00, suggesting a potential upside of 127.27%. Design Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 9.89%. Given ImmunoPrecise Antibodies' stronger consensus rating and higher possible upside, equities research analysts clearly believe ImmunoPrecise Antibodies is more favorable than Design Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunoPrecise Antibodies
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Design Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

ImmunoPrecise Antibodies has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoPrecise Antibodies$18.16M4.43-$20.13M-$1.16-1.52
Design TherapeuticsN/AN/A-$49.59M-$0.99-3.68

Design Therapeutics has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -190.76%. Design Therapeutics' return on equity of -22.85% beat ImmunoPrecise Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunoPrecise Antibodies-190.76% -88.87% -49.26%
Design Therapeutics N/A -22.85%-22.02%

ImmunoPrecise Antibodies has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.

In the previous week, ImmunoPrecise Antibodies had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for ImmunoPrecise Antibodies and 0 mentions for Design Therapeutics. ImmunoPrecise Antibodies' average media sentiment score of 0.68 beat Design Therapeutics' score of 0.00 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the media.

Company Overall Sentiment
ImmunoPrecise Antibodies Positive
Design Therapeutics Neutral

6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are owned by insiders. Comparatively, 31.2% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

ImmunoPrecise Antibodies beats Design Therapeutics on 8 of the 15 factors compared between the two stocks.

Get ImmunoPrecise Antibodies News Delivered to You Automatically

Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IPA vs. The Competition

MetricImmunoPrecise AntibodiesMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$74.60M$1.97B$5.47B$8.95B
Dividend YieldN/AN/A5.25%4.06%
P/E Ratio-1.5235.7727.0020.10
Price / Sales4.4315.86428.95120.24
Price / CashN/A54.5536.8257.86
Price / Book1.898.567.985.56
Net Income-$20.13M-$62.39M$3.16B$248.40M
7 Day Performance66.04%4.26%2.39%4.67%
1 Month Performance162.77%4.34%2.18%6.64%
1 Year Performance77.78%9.18%33.82%21.31%

ImmunoPrecise Antibodies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IPA
ImmunoPrecise Antibodies
2.523 of 5 stars
$1.76
+8.0%
$4.00
+127.3%
+76.0%$74.60M$18.16M-1.5280News Coverage
DSGN
Design Therapeutics
0.3701 of 5 stars
$3.37
-5.6%
$4.00
+18.7%
+4.0%$202.66MN/A-3.4040
VOR
Vor Biopharma
3.9433 of 5 stars
$1.62
+52.8%
$5.63
+247.4%
+164.9%$202.44MN/A-0.98140Options Volume
Gap Up
High Trading Volume
ACIU
AC Immune
2.7562 of 5 stars
$2.03
+1.0%
$12.00
+491.1%
-40.5%$201.82M$31.02M-3.50140
ESPR
Esperion Therapeutics
4.2262 of 5 stars
$0.98
-0.9%
$7.00
+611.1%
-51.3%$196.93M$332.31M-1.23200Positive News
PROK
ProKidney
0.7394 of 5 stars
$0.59
-11.5%
$3.50
+491.1%
+68.8%$195.73M$80K-0.993Trending News
Gap Up
High Trading Volume
KOD
Kodiak Sciences
4.1283 of 5 stars
$3.73
+0.8%
$9.00
+141.3%
+58.5%$195.23MN/A-1.0390
SLS
SELLAS Life Sciences Group
0.1221 of 5 stars
$2.19
+12.3%
N/A+77.9%$194.57M$1M-5.7610High Trading Volume
LRMR
Larimar Therapeutics
1.8903 of 5 stars
$2.89
-4.6%
$18.50
+540.1%
-59.5%$194.01MN/A-1.9430
CRGX
CARGO Therapeutics
2.1022 of 5 stars
$4.12
-1.7%
$15.00
+264.1%
-71.4%$193.20MN/A-0.89116Trending News
Analyst Forecast
Gap Up
CYBN
Cybin
2.9117 of 5 stars
$8.39
+2.9%
$86.00
+925.0%
N/A$193.17MN/A-1.9250News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:IPA) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners